Theranostics in brain tumors: Tolboom and European colleagues provide a state-of-the-art overview of theranostic approaches in neurooncology, including specific tumor entities, potential molecular targets, and strategies to enhance effectiveness.
Page 167
α-Synuclein assays in PD: Seibyl looks at expanding promise for α-synuclein seeding amplification assays in earlier diagnosis of Parkinson disease and timely management of therapies that target synucleinopathies.
Page 174
212Pb: a post-177Lu/225Ac blockbuster? Zimmermann reviews current progress in large-scale supply of 212Pb and surveys current industry involvement in development and production, highlighting the potential for future replacement of 225Ac with 212Pb in α-emitter therapies.
Page 176
HER2-sdAb phase II trial: Gondry and colleagues analyze trial results on the repeatability of uptake quantification and extended safety of the [68Ga]Ga-NOTA-anti-human epidermal growth factor receptor 2 single-domain antibody in PET/CT imaging of locally advanced or metastatic breast carcinoma.
Page 178
Discordant volume in GEP NENs: Chan and colleagues investigate differing tumor volumes on [18F]FDG and [68Ga]Ga-DOTATATE PET/CT as a potential prognostic biomarker in patients with advanced gastroenteropancreatic neuroendocrine neoplasms.
Page 185
[18F]TFB PET/CT in recurrent DTC: Ventura and colleagues compare [18F]tetrafluoroborate PET with high-activity posttherapeutic [131I]iodine whole-body scintigraphy and SPECT/CT in recurrent differentiated thyroid cancer and with [18F]FDG PET/CT in suspected dedifferentiation.
Page 192
68Ga-FAP-2286 PET in bladder cancer: Koshkin and colleagues present experience with the novel fibroblast activation protein–peptide binder 68Ga-FAP-2286 in PET imaging and staging of patients with muscle-invasive bladder cancer.
Page 199
18F-FAPI-04 PET/CT in pancreatic cancer: Li and colleagues explore the ability of 18F-fibroblast activation protein inhibitor–04 PET/CT to diagnose and stage pancreatic ductal adenocarcinoma and compare findings with those from 18F-FDG PET.
Page 206
68Ga-FAPI PET/CT in gastric cancer: Miao and colleagues ask whether imaging parameters from 18F-FDG and 68Ga-fibroblast activation protein inhibitor–04 PET/CT can predict early pathologic response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer.
Page 213
[18F]FES PET breast procedure guideline: Mankoff, Balogová, and coauthors offer a summary of their recently published SNMMI procedure standard/European Association of Nuclear Medicine practice guideline for estrogen receptor imaging with 16α-[18F]fluoro-17β-estradiol PET in breast cancer.
Page 221
Radioligand therapy in prostate cancer: Rahbar and Boegemann underscore the need for robust studies of targeted radioligands, including comparisons with established clinical treatments, taking as an example 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Page 224
PSMAfore trial design: Sartor and colleagues respond to commentary by Rahbar and Boegemann and discuss critical factors in the design of the PSMAfore phase 3 trial of 177Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer.
Page 226
PRRT in metastatic insulinoma: Friebe and colleagues study somatostatin receptor–positive metastatic malignant insulinoma, evaluating the efficacy of peptide receptor radionuclide therapy for hypoglycemia, changes in medication after therapy, and resulting progression-free and overall survival.
Page 228
PRRT outcome prediction in GEP NETs: Mileva and colleagues use multimodality imaging and tumor dosimetry to identify factors predicting outcomes in peptide receptor radionuclide therapy of gastroenteropancreatic neuroendocrine tumors.
Page 236
223Ra dose within bone biopsy specimens: Benabdallah and colleagues determine the distribution of clinically approved [223Ra]RaCl2 in bone metastatic castration-resistant prostate cancer to inform activity distribution and dose at the near-cell scale.
Page 245
Role of FAPα in SFTs: Hamacher and colleagues report on the expression pattern of fibroblast activation protein α in solitary fibrous tumors and its potential use as a radiotheranostic target.
Page 252
177Lu-DOTATATE and mesenteric mass: Al Mansour and colleagues look at the question of whether desmoplastic mesenteric masses, present in most small-intestinal neuroendocrine tumors, are refractory to 177Lu-DOTATATE peptide receptor radionuclide therapy.
Page 258
Updated DOSISPHERE-01 trial analysis: Garin and colleagues describe long-term results on overall survival from this study that showed improvement in response and survival with personalized dosimetry of 90Y-loaded glass microspheres in nonoperable locally advanced hepatocellular carcinoma.
Page 264
Personalizing 90Y radioembolization dosimetry: Soulen and Rilling provide perspective on history and challenges that have accompanied the approval for 90Y radioembolization techniques and offer commentary on a related article in this issue of JNM.
Page 270
SIRT particles for ICC: Wagemans and colleagues compare absorbed doses, toxicities, and responses with 90Y-glass, 90Y-resin, and 166Ho-labeled poly(l-lactic acid) microspheres for selective internal radiation therapy in locally advanced intrahepatic cholangiocarcinoma.
Page 272
Combined FFR/iFR: de Winter and colleagues compare [15O]H2O PET–derived absolute myocardial perfusion between vessels with concordant and discordant fractional flow reserve and instantaneous wave-free ratio measurements to elucidate the hemodynamic significance of discordance.
Page 279
Multicenter molecular imaging after MI: Strunk and colleagues report on the reproducibility of murine quantitative inflammation and fibroblast activation images acquired after myocardial infarction at 2 facilities.
Page 287
CD69 PET in inflammatory arthritis: Puuvuori and colleagues evaluate a CD69-targeting PET agent for early disease detection in a mouse model of inflammatory arthritis, with clinical promise for identification of activated immune cells in rheumatoid arthritis onset.
Page 294
(R)-[18F]YH134 PET of MAGL: He and colleagues explore in mouse and rat brains the kinetic properties of this [18F]T-401 derivative as a novel PET tracer for imaging monoacylglycerol lipase.
Page 300
CBF from florbetaben and water PET/MRI: Fettahoglu and colleagues detail a quantitative cerebral blood flow imaging method combining early [18F]florbetaben with phase-contrast MRI using simultaneous PET/MRI, providing CBF and amyloid burden measurement in 1 session in memory disorders.
Page 306
Tumor location and prognosis in DLBCL: Girum and colleagues determine whether identification of tumor locations relative to spleen location in baseline [18F]FDG PET/CT images predicts survival in diffuse large B-cell lymphoma and improves the predictive value of other metrics.
Page 313
Portable PET comparisons in humans: Bartlett and colleagues perform a within-participant comparison of fully quantified [18F]FDG dynamic scans in healthy volunteers using a standard Biograph mCT scanner and a portable CerePET scanner.
Page 320
11C-Met PET in acromegaly: Haberbosch and colleagues present a case study illustrating the dual role of 11C-Met PET in acromegaly, confirming remission and detecting recurrence.
Page 327
- © 2024 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.